AlzeCure Pharma publishes its Annual Report for 2022

Published April 5, 2023

STOCKHOLM, SE / ACCESSWIRE / April 05, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that its Annual Report for 2022 has been published.

"With a successful 2022 behind us during which we reached the significant milestone of becoming a Phase II company, along with growing interest in both our research and the Alzheimer's field as a whole, as well as increased support from our main owners, I look forward to continuing the positive development of AlzeCure together with our talented and ambitious employees and partners. The strong beginning of 2023, with significant success in our projects, strengthens us in our work to develop innovative, groundbreaking drugs in the fields of Alzheimer's disease, pain and other severe diseases," says Martin Jönsson, CEO of AlzeCure Pharma.

The Annual Report is attached as a PDF and is available on the company's website,

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit


Alzecure AR 2022 ENG

SOURCE: AlzeCure Pharma

View source version on


News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.